Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acalabrutinib - Acerta Pharma/AstraZeneca

Next Previous
X
Search
Drug Profile

Acalabrutinib - Acerta Pharma/AstraZeneca

Alternative Names: Acalabrutinib maleate; ACP-196; CALQUENCE; Calquence

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; AstraZeneca; Biologics Inc; National Institutes of Health (USA)
  • Class Anti-infectives; Antineoplastics; Antirheumatics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II B-cell lymphoma; Bladder cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Phase I/II B-cell prolymphocytic leukaemia; Follicular lymphoma; Glioblastoma; Multiple myeloma
  • No development reported Infections
  • Discontinued COVID 2019 infections; Haematological malignancies; Rheumatoid arthritis

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(In volunteers) in USA (PO, Capsule)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(In volunteers) in USA (PO, Liquid)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(In volunteers) in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top